NLM Digital Collections

Search

Start Over Genre Technical Report ✖Remove constraint Genre: Technical Report Copyright Copyright may apply ✖Remove constraint Copyright: Copyright may apply

1541. Modulator treatments for cystic fibrosis: effectiveness and value : final evidence report and meeting summary

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 7, 2018
Subject(s):
Cystic Fibrosis -- drug therapy
Cystic Fibrosis Transmembrane Conductance Regulator -- therapeutic use
Clinical Trials as Topic
Cost of Illness
Cost-Benefit Analysis
Cystic Fibrosis Transmembrane Conductance Regulator -- adverse effects
Treatment Outcome
Humans
United States

1542. Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, July 3, 2018
Subject(s):
Calcitonin Gene-Related Peptide Receptor Antagonists -- therapeutic use
Migraine Disorders -- drug therapy
Migraine Disorders -- prevention & control
Calcitonin Gene-Related Peptide Receptor Antagonists -- adverse effects
Chronic Disease
Clinical Trials as Topic
Treatment Outcome
Humans
United States

1543. Elagolix for treating endometriosis: final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Endometriosis -- drug therapy
Gonadotropin-Releasing Hormone -- antagonists & inhibitors
Analgesics -- adverse effects
Analgesics -- therapeutic use
Cost-Benefit Analysis
Pain -- drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

1544. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Immunologic Factors -- therapeutic use
Immunomodulation
Psoriasis -- drug therapy
Certolizumab Pegol -- therapeutic use
Clinical Trials as Topic
Cost-Benefit Analysis
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Quality of Life
Treatment Outcome
Humans
United States

1545. Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):
Amyloidosis, Familial -- drug therapy
RNA, Small Interfering -- therapeutic use
Amyloid Neuropathies, Familial -- drug therapy
Amyloidosis, Familial -- complications
Clinical Trials as Topic
Cost-Benefit Analysis
RNA, Small Interfering -- adverse effects
RNA, Small Interfering -- economics
Treatment Outcome
Humans
United States

1546. Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):
Androgen Antagonists -- therapeutic use
Prostatic Neoplasms -- drug therapy
Androgen Antagonists -- adverse effects
Cost-Benefit Analysis
Disease Progression
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

1547. Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, November 25, 2018
Subject(s):
Angioedemas, Hereditary -- drug therapy
Angioedemas, Hereditary -- prevention & control
Antibodies, Monoclonal, Humanized -- therapeutic use
Complement C1 Inhibitor Protein -- therapeutic use
Kallikreins -- antagonists & inhibitors
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Complement C1 Inhibitor Protein -- adverse effects
Complement C1 Inhibitor Protein -- economics
Cost-Benefit Analysis
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

1548. Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 3, 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Treatment Outcome
Humans
United States

1549. Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2018
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Asthma -- drug therapy
Inflammation -- drug therapy
Antibodies, Monoclonal -- adverse effects
Antibodies, Monoclonal -- economics
Biological Therapy
Cost-Benefit Analysis
Hypersensitivity -- drug therapy
Inflammation -- complications
Treatment Outcome
Humans
United States

1550. Assessment and synthesis of selected Medicaid eligibility, enrollment, and renewal processes and systems in six states

Author(s):
Zylla, Emily, author
Au-Yeung, Caroline, author
Lukanen, Elizabeth, author
Worrall, Christina, author
Publication:
[Minneapolis, Minnesota] : State Health Access Data Assistance Center, October 19, 2018
Subject(s):
Eligibility Determination -- organization & administration
Medicaid -- statistics & numerical data
Electronic Data Processing
Federal Government
Income
Patient Navigation
State Government
Humans
United States
United States. Department of Health and Human Services.
United States.
State Children's Health Insurance Program (U.S.)